A research team at Helmholtz Zentrum München has published the design of a single-molecule quintuple agonist that activates GLP-1, GIP, and three PPAR receptor subtypes. Published in Nature on April 30, 2026, the conjugate outperformed semaglutide and tirzepatide dual agonism in obese diabetic mouse models.